Bioventix PLC
BVXP.L operates in the healthcare diagnostics sector, providing products and services related to medical research and biotechnology.
Business. BVXP.L is a biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models typical of the industry. It is listed on the London Stock Exchange under the ticker BVXP.L. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BVXP.L is a biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models typical of the industry. It is listed on the London Stock Exchange under the ticker BVXP.L. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
BVXP.L maintains a strong liquidity position, with a current ratio of 9.17, indicating that the company has significantly more current assets than current liabilities. The company has no long-term debt, and its total liabilities are relatively low at 1,312,050 GBP compared to its total equity of 11,551,720 GBP, resulting in a debt-to-equity ratio of 0.0.
The company's profitability is robust, with a return on equity (ROE) of 65.66% and a return on assets (ROA) of 58.96%. These figures suggest that BVXP.L is effectively utilizing its equity and assets to generate profits. The operating income of 9,903,570 GBP and net income of 7,584,440 GBP further support the company's strong financial performance.
BVXP.L's revenue is concentrated in the healthcare diagnostics segment, with no disclosed geographic breakdown. The company's primary source of revenue is derived from its operations in the Biotechnology & Medical Research industry. There is no indication of significant geographic diversification in the provided data.
The company's growth trajectory appears stable, with a recent actual revenue of 13,116,000 GBP compared to a mean revenue estimate of 12,500,000 GBP. The slight outperformance suggests that the company is meeting or slightly exceeding analyst expectations. The mean EPS estimate of 1.36 GBP is slightly lower than the last actual EPS of 1.43 GBP, indicating consistent earnings performance.
BVXP.L faces low liquidity and dilution risks, with no immediate filing-based flags detected. The company has no long-term debt and a low dilution potential, as indicated by the absence of dilutive securities in the shares outstanding data. The company's financial structure supports a stable capital base without the need for near-term equity issuance.
Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's financial performance has been consistent with analyst estimates, and there are no disclosed risks or events that would suggest a near-term change in its financial trajectory.
- BVXP.L has a strong liquidity position with a current ratio of 9.17 and no long-term debt.
- The company's profitability is robust, with a return on equity of 65.66% and a return on assets of 58.96%.
- Revenue is concentrated in the healthcare diagnostics segment, with no significant geographic diversification.
- The company's recent financial performance has met or slightly exceeded analyst expectations.
- BVXP.L faces low liquidity and dilution risks, with no immediate filing-based flags detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,36 |
| Revenue | —no estimate | —no estimate | 12,5M GBP |
| Operating income | —no estimate | —no estimate | 9,4M GBP |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- BVXP.L Market data — financials · 2026-05-27
- Bioventix PLC Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Peter HarrisonChief Executive Officer, Executive Director